Pantoprazole Milpharm (Pantoprazole)

Pantoprazole Milpharm is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining.
• Erosive oesophagitis: supports mucosal healing and reduces recurrence.
• Peptic ulcer disease: facilitates ulcer healing and helps prevent relapse.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid production, leading to a sustained reduction in gastric acidity and an elevated gastric pH.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: excess gas.
• Constipation: infrequent.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): requires immediate medical attention.
• Clostridioides difficile infection: may present with persistent diarrhoea.
• Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia.
• Bone fractures: associated with long‑term use.
• Liver enzyme elevation: indicates possible hepatic stress.
• Acute interstitial nephritis: rare kidney inflammation.

When prescribing Pantoprazole Milpharm, clinicians should consider several safety aspects:

• Assess patient history: evaluate for prior hypersensitivity to PPIs.
• Monitor electrolytes: check magnesium and potassium levels during prolonged therapy.
• Evaluate renal function: adjust use in severe renal impairment if needed.
• Review concomitant medications: assess risk of reduced absorption of drugs requiring acidic pH.
• Pregnancy and lactation: use only if clearly needed, weighing potential benefits against risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH.
• Atorvastatin: increased plasma concentrations, raising risk of myopathy.
• Clopidogrel: diminished antiplatelet effect, potentially compromising cardiovascular protection.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR values; monitor coagulation parameters.
• Methotrexate: reduced renal clearance may increase toxicity.
• Digoxin: slight increase in serum levels; observe for signs of digoxin toxicity.